Abstract:Hypoxia imaging agents can play an important role in the tumor treatment by avoiding the worse effect of radiotherapy and chemotherapy due to the tumor hypoxia. Due to the small size and easy coordination, tricarbonyl technetium-99m can be used to label a wide range of imaging agents. In this work, the tricarbonyl Tc-99m labeled small-sized hypoxia imaging agents containing 2-nitroimidazoles were prepared, which have different carbon chain lengths between cyclopentadienyl and 2-nitroimidazole, and which have one or two 2-nitroimidazole groups. The results of S180 cell experiment and biodistribution indicated that these molecules have different hypoxic selectivity. When contains one 2-nitroimidazole, as the carbon chain lengthens, which means the molecular volume becomes larger, hypoxia cellular uptake and selectivity decrease in S180 cell uptake experiment. In biodistribution study in mice bearing S180 tumor, Tc-2 (1-cyclopentadienyl-5-(2-nitro-1H-imidazol-1-yl)-pentan-1-one tricarbonyl Tc-99m complex), which has intermediate carbon chain, is better due to the more complex factors. Its tumor/blood (T/B) ratio is 3.56 & PLUSMN; 0.25, tumor/muscle(T/M) ratio is 1.73 & PLUSMN; 0.29 and tumor uptake is 2.23 & PLUSMN; 0.24%ID/g at 2 h. Comparing to other tricarbonyl technetium complexes containing one 2-nitroimidazole, the complexes in this work have an advantage in tumor/blood ratio and tumor uptake. This suggests that the small-volume cyclopentadienyl may have an advantage when used as a ligand. When contains two 2nitroimidazole groups, the complex, 1-cyclopentadienyl-5-di(2-(2-nitro-1H-imidazol-1-yl)ethyl)amino-pentan1-one tricarbonyl Tc-99m complex (Tc-4), has the better results in the cell experiment than those which contain one 2-nitroimidazole group. Thus the hypoxia imaging agent contains two 2-nitroimidazole groups is more advantageous, but further modifications of Tc-4 are needed to improve its clearance rate in the blood, because the increased lipophilicity leads to a decrease in the T/B ratio of Tc-4. In conclusion, small volume hypoxia imaging agents with two 2-nitroimidazole groups may be the trend of development.

Preparation of Tc-carbonyl Complexes of Tryptophan and Histidine and Biodistribution in Mice Bearing S180 Tumor

Synthesis and Biodistribution of the 99m Tc Nitrido Complex with 2-(4-nitro-1h-imidazolyl)ethyl Dithiocarbamate (NIET)

Preparation of ~(99)Tc~m-Dtpa-folate and Biodistribution Study in Athymic Mice

Synthesis and Biological Studies of 99m Tc(HYNIC–MFL)(tricine)(TPPTS) As a Novel Tumor Imaging Agent

[Tc-99M(co)(3)](+) Labeled Histidine Derivative Containing 4-Nitroimidazole: Synthesis, Biodistribution As A Tumor Hypoxia Imaging Agent

Synthesis and Biological Evaluation of a Novel 99mtc Cyclopentadienyl Tricarbonyl Complex ([(Cp-R)99mtc(co)3]) for Sigma-2 Receptor Tumor Imaging

Preliminary Studies of a Novel Cyclopentadienyl Tricarbonyl Technetium-99M Fatty Acid Derivative for Myocardical Imaging.

<sup>99m</sup>Tc-Labeled Bombesin(7−14)NH<sub>2</sub>with Favorable Properties for SPECT Imaging of Colon Cancer

Biodistribution and Pharmacokinetics of 99tcm Labeled Carbohydrated Peptides in Mice Bearing Tumors

Tc-99m-Labeled Bombesin(7-14)Nh2 With Favorable Properties For Spect Imaging Of Colon Cancer

Synthesis And Biodistribution Of Novel Tc-99m Labeled 4-Nitroimidazole Dithiocarbamate Complexes As Potential Agents To Target Tumor Hypoxia

Preparation and biodistribution of a (99m)Tc tricarbonyl complex with deoxyglucose dithiocarbamate as a tumor imaging agent for SPECT.

Preparation and Rats' Pharmacokinetics of TM208 HP-β-CD Inclusion Complexes

Synthesis and Biodistribution of 99Mtc-Carbonyltechnetium-labeled Fatty Acids

Synthesis of 99mTc-aroylhydrazinocarbonylmethyliminodiacetic acids and their animal study, hepatobiliary pharmaceuticals

Preparation and Biological Evaluation of 99Mtc-N4ipa for Single Photon Emission Computerized Tomography Imaging of Hypoxia in Mouse Tumor

Synthesis and Biodistribution of 99Tcm-MAG2-Ade as A Tumor Imaging Agent

Synthesis and bioevaluation of the cyclopentadienyl tricarbonyl technetium-99m 2-nitroimidazole derivatives for tumor hypoxia imaging

Preparation and Evaluation of Tc-99m-Labeled Dimeric Tyr(3)-Octreotide in the Ar42j Tumor Model

Synthesis and Evaluation Of111in-Dota-mab109 Monoclonal Antibody for Potential SPECT Molecular Imaging

(99M)tc-Labeled Dimeric Octreotide Peptide: a Radiotracer with High Tumor Uptake for Single-Photon Emission Computed Tomography Imaging of Somatostatin Receptor Subtype 2-Positive Tumors.